loading page

Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS-CoV-2 targeted therapy
  • +9
  • Hua Zhu,
  • Zilei Wang,
  • Chuanke Zhao,
  • Chuangui Li,
  • Song Liu,
  • Jin Ding,
  • Chengxue He,
  • Jiayue Liu,
  • Bin Dong,
  • Zhi Yang,
  • Qi Liu,
  • Youping Liu
Hua Zhu
Beijing Cancer Hospital
Author Profile
Zilei Wang
Southwest Medical University
Author Profile
Chuanke Zhao
Beijing Cancer Hospital
Author Profile
Chuangui Li
The First Affiliated Hospital of Hebei North University
Author Profile
Song Liu
Beijing Cancer Hospital
Author Profile
Jin Ding
Beijing Cancer Hospital
Author Profile
Chengxue He
Beijing Cancer Hospital
Author Profile
Jiayue Liu
Beijing Cancer Hospital
Author Profile
Bin Dong
Beijing Cancer Hospital
Author Profile
Zhi Yang
Beijing Cancer Hospital
Author Profile
Qi Liu
Peking University Shenzhen Graduate School
Author Profile
Youping Liu
Southwest Medical University

Corresponding Author:[email protected]

Author Profile

Abstract

Objectives The aim of this study was to assess the potential of noninvasive and repeated monitoring of rhACE2 distribution and content in organs using the ACE2-specific nuclide probe 68Ga-HZ20. Methods We optimized the labeling conditions of the probe and evaluated its safety. A mouse organ in situ rhACE2 high-aggregation model was constructed for the first time, and in vivo real-time PET imaging of rhACE2 was performed using the ACE2-specific PET agent 68Ga-HZ20. The distribution and uptake of the probe were analyzed, and the model was validated. Results This radiotracer exhibited reliable radiochemical properties in vitro and maintained a high affinity for rhACE2 in vivo. In terms of probe uptake, 68Ga-HZ20 showed a good target-to-nontarget ratio, and the correlation between the uptake value of the probe and the dose of rhACE2 was >90% in both models; the probe was rapidly cleared from the circulatory system and excreted by the kidneys and urinary system. No organs were damaged after the injection of high doses of probe. Conclusions This technology for noninvasively and repeatedly monitoring the content and distribution of rhACE2 in vivo aids in clarifying the resident capacity of rhACE2 in organs and in analyzing the preventive effect of rhACE2 against SARS-CoV-2 and the effectiveness of therapies for COVID-19.
08 May 2023Submitted to Journal of Medical Virology
08 May 2023Submission Checks Completed
08 May 2023Assigned to Editor
08 May 2023Review(s) Completed, Editorial Evaluation Pending
17 May 2023Reviewer(s) Assigned
24 Aug 2023Editorial Decision: Revise Major
26 Sep 20231st Revision Received
28 Sep 2023Assigned to Editor
28 Sep 2023Submission Checks Completed
28 Sep 2023Review(s) Completed, Editorial Evaluation Pending
01 Oct 2023Reviewer(s) Assigned
13 Oct 2023Editorial Decision: Revise Minor
21 Oct 20232nd Revision Received
21 Oct 2023Assigned to Editor
21 Oct 2023Submission Checks Completed
21 Oct 2023Review(s) Completed, Editorial Evaluation Pending
24 Oct 2023Reviewer(s) Assigned
31 Oct 2023Editorial Decision: Accept